Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2021
ICER publishes final evidence report and policy recommendations on roxadustat
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
Posted by Michael Wonder on 02 Mar 2021
What could Biden’s possible bid for a national health technology assessment entity look like?
2 March 2021 - The U.S. has never had a publicly funded, independent health technology assessment organisation to evaluate prescription drugs, ...
Posted by Michael Wonder on 02 Mar 2021
ICER publishes Final Evidence Report and policy recommendations on new therapies for high cholesterol
2 March 2021 - For bempedoic acid, independent appraisal committee votes that the evidence is not adequate to demonstrate a net ...
Posted by Michael Wonder on 15 Feb 2021
Drug prices by committee: one way Biden could lower costs
11 February 2021 - Many countries use independent review boards to balance innovation and profit. ...
Posted by Michael Wonder on 12 Feb 2021
ICER releases draft evidence report on therapies for multiple myeloma
11 February 2021 - Public comment period now open until March 11, 2021; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 10 Feb 2021
Due to aducanumab’s new PDUFA date, ICER extends timeline for Alzheimer’s disease assessment
10 February 2021 - The ICER announced today it has extended its timeline for assessing the comparative clinical effectiveness and ...
Posted by Michael Wonder on 09 Feb 2021
The Biden administration needs to look beyond ICER for evaluating drug therapies
9 February 2021 - As breakthrough drugs stream out of biopharmaceutical laboratories, how much they should cost and who will ...
Posted by Michael Wonder on 28 Jan 2021
ICER publishes evidence report on roxadustat for treating anaemia in chronic kidney disease
28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...
Posted by Michael Wonder on 22 Jan 2021
ICER publishes evidence report on therapies for high cholesterol
22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...
Posted by Michael Wonder on 22 Jan 2021
ICER releases draft evidence report on therapies for lupus nephritis
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 18 Jan 2021
ICER issues correction to final evidence report on new therapies for bladder cancer
15 January 2021 - After correcting an input to the cost-effectiveness model, ICER’s health-benchmark price benchmark range for nadofaragene firadenovec has ...
Posted by Michael Wonder on 12 Jan 2021
ICER identifies most significant 2019 US drug price hikes — even after rebates — that were not supported by new clinical evidence
12 January 2021 - Out of 10 identified drugs that had substantial 2019 price increases on top of already high current ...
Posted by Michael Wonder on 17 Dec 2020
ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
Posted by Michael Wonder on 10 Dec 2020
ICER to assess treatments for atopic dermatitis
10 December 2020 - Report will be subject of New England CEPAC meeting in July 2021; draft scoping document open to ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...